Bayer: UBS lowers price target

(CercleFinance.com) - The analyst lowers his price target by 6% due to uncertainties surrounding ongoing litigation.
UBS therefore confirms its neutral recommendation on the stock, lowering its target price to E32 (from E34) - this still represents 18% upside potential.

Litigation uncertainty has increased following recent verdicts. We are increasing our discount on the group's value to reflect this situation, and lowering our target price, UBS says.

The broker points out that the group has so far won 10 of the 16 Roundup-related lawsuits, and that its strategy should continue to be to systematically appeal unfavourable judgments, with the aim of reducing the amount of damages it is ordered to pay.

However, UBS is concerned about a possible upward revision of the company's legal reserves, which currently stand at E6.1bn.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.